Novo Nordisk Defends Semaglutide Alzheimer's Trials After Studies Miss Goals

2025-12-02 07:00:51

(MENAFN- AsiaNet News)

Novo Nordisk (NVO) reportedly defended its decision to test Semaglutide, its GLP-1 therapy, in Alzheimer's disease on Tuesday, saying it launched pivotal trials in 2020 based on evidence from human studies, animal research and real-world findings.

Speaking at the Clinical Trials in Alzheimer's Disease meeting in San Diego, Peter Johannsen, Novo's international medical vice president, acknowledged criticism that the studies had design flaws, according to a Reuters report.

He supposedly said the lack of statistically significant slowing of cognitive decline did not change the rationale for conducting them, calling it“a scientific question that needed an answer.”

Get updates to this developing story directly on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

MENAFN02122025007385015968ID1110427866

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.